ACADIA Pharmaceuticals Officially Opens New Chemistry R&D Facility in Sweden
Friday September 16, 3:01 am ET
SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD - News), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today officially opened its modern chemistry research and development facility in Malmo, Sweden. The new facility consolidates ACADIA's presence in Scandinavia and provides increased access to a highly skilled and well-educated workforce in the biotechnology hub of the Medicon Valley region.
ACADIA's Chief Executive Officer, Uli Hacksell, Ph.D., said, "Our new state-of-the-art R&D facility demonstrates our commitment to strengthen our operations in medicinal chemistry and underscores our firm belief that the discovery of new potential drug candidates is accelerated when medicinal chemistry is a core part of the discovery engine and introduced at an early stage of the process."
Mark R. Brann, Ph.D., President and Chief Scientific Officer at ACADIA, said, "As our product candidates advance into late-stage development, our medicinal chemistry operations in Malmo will play a key role in supporting these programs while discovering new product candidates to introduce into our pipeline. At ACADIA, our teams of chemists, biologists, and clinical scientists work closely together to produce drug candidates in a highly efficient manner."
ACADIA's new 3,000 square meter custom-built chemistry facility is home to a significant portion of the company's research scientists. The chemists at ACADIA play an important role in all aspects of the company's research and development efforts. They are responsible for building a diverse compound library, identifying and optimizing lead compounds that are the most promising starting points of drug discovery projects, and directing production of the compounds so that they are suitable for human use. ACADIA's biological research and clinical development activities are conducted at the company's headquarters in San Diego, California.
"The Medicon Valley region is home to greater than 60 percent of Scandinavia's pharmaceutical and biotechnology companies and provides ACADIA with access to a strong scientific talent pool," said Bo-Ragnar Tolf, Ph.D., Vice President, Chemistry and Managing Director of Swedish subsidiary ACADIA Pharmaceuticals AB. <snip> |
